Free Trial

Morphic Q4 2023 Earnings Report

Morphic EPS Results

Actual EPS
-$0.94
Consensus EPS
-$0.89
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Morphic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Morphic Announcement Details

Quarter
Q4 2023
Time
N/A
Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry. 

Morphic Earnings Headlines

Morphic Ethical Equities Fund Limited
Eli Lilly acquires Morphic in IBD portfolio expansion
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
MORF Jan 2025 25.000 put (MORF250117P00025000)
See More Morphic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Morphic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Morphic and other key companies, straight to your email.

About Morphic

Morphic (NASDAQ:MORF), a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

View Morphic Profile

More Earnings Resources from MarketBeat